Science Wins, Total Cancer - The world's first CDK4/6 inhibitor continues to respond to World Cancer Day to help Chinese patients fight advanced breast cancer

Every year on February 4th, World Cancer Day is established by the International Alliance against Cancer (UICC) and the World Health Organization (WHO) to promote cancer prevention and treatment worldwide, to raise the level of early diagnosis of cancer and reduce the incidence of cancer, and this year's theme is "Caring for Patients, Working Together against Cancer (I am and I will)".
years of joint efforts from all walks of life, we are pleased to see that the survival status of all types of cancer patients continue to improve, but at the same time, also need to pay attention to the incidence of various types of cancer is quietly changing.
breast cancer: The incidence of breast cancer has peaked, with 120,000 Chinese patients dying each year, according to the World Health Organization's International Agency for Research on Cancer (IARC) 2020, the latest global cancer burden data show that in 2020, the number of new cancer cases worldwide reached 19.29 million, of which 2.26 million new cases of breast cancer, more than 2.2 million cases of lung cancer, breast cancer has replaced lung cancer as the world's largest cancer.
For Patients in China, breast cancer ranks first in the incidence of malignant tumors in women all year round, with about 304,000 cases per year, of which about 3% to 10% of women have distant metastasis at the time of diagnosis.
even in early stage patients, 30% to 40% develop advanced breast cancer.
the five-year survival rate of patients with advanced breast cancer in China is only 20%, and the overall medium survival time is 2 to 3 years, which is significantly lower than that of developed countries.
the same set of statistics from the IARC, there will be 3 million cancer deaths and 121,000 breast cancer deaths in China in 2020.
Enterprising therapists: continuous improvement of treatment, so that patients have "two full" nearly a decade, domestic clinical oncologists and related practitioners have been committed to improving the clinical treatment of breast cancer countermeasures, from surgical treatment, chemotherapy, endocrine treatment to today's targeted treatment, advanced breast cancer treatment methods continue to emerge and change, so that the survival of patients can be greatly extended, but also achieved "dignity to survive."
breast cancer has become a "preventable and treatable" chronic disease, which is a stage victory for cancer prevention and treatment in China.
, longer disease management times also bring more clinical challenges.
health China Action - Cancer Prevention and Control Implementation Program (2019-2022) jointly issued by various ministries in 2019, the goal of early diagnosis and treatment of breast cancer, standardized diagnosis and treatment, and improving the overall survival rate is emphasized.
patient-centered, "all-round, full-cycle" "two-full" disease management concept, has become the next stage of breast cancer treatment in China an important point.
National Cancer Center/Chinese Academy of Medical Sciences Cancer Hospital National New Drug (Anti-Tumor) Clinical Research Center (GCP Center) Director of the National Cancer Quality Control Center Breast Cancer Expert Committee Chairman Professor Xu Binghe Professor National Cancer Center / Chinese Academy of Medical Sciences Cancer Hospital National New Drug (Anti-Tumor) Clinical Research Center (GCP Center) Director, National Cancer Quality Control Center Breast Cancer Expert Committee Chairman Professor Xu Binghe said: "The overall level of breast cancer treatment in China in recent years has made remarkable progress. The patient's five-year survival rate has exceeded 83%, but there is still a gap compared with the United States, which is as high as 90 percent.
First of all, because breast cancer screening and early diagnosis is not as good as in Western countries, developed countries in the phase I detection rate of more than 40%, and China's phase I detection rate of about 20% to 25%;
in order to regulate breast cancer screening, treatment and follow-up, domestic associations and institutions have also developed a number of guidelines and norms, hope that the future clinical treatment of breast cancer will be more and more standardized.
" Common Mission: Science Wins, Co-ker Cancer Benefits from the entry into China of the world's first targeted drug for HR/Her2-Advanced Breast Cancer in 2018 - CDK4/6 inhibitor Virbosili, and the concept of "both" begins to blossom in the field of breast cancer.
in the latest edition of the China Guidelines for the Standard Diagnosis and Treatment of Advanced Breast Cancer (2020 Edition), the CDK4/6 inhibitor-targeted joint program is recommended as the first-line standard treatment for patients with HR-/HER2-advanced breast cancer.
This positive breaks the previous treatment of advanced breast cancer over-reliance on single chemotherapy treatment situation, to fill the previous treatment gap of HR/HER2-patients, after the market real-world research shows that the median non-progressive survival of the treatment of HR-/HER2-patients by erbasilli, in improving the five-year survival rate and quality of life have played a breakthrough role in raising the patient's survival and providing more hope for survival.
, the treatment has treated more than 350,000 people in nearly 100 countries and regions around the world and has benefited nearly 10,000 Chinese patients.
While conquering diseases with scientific power, medical institutions, medical experts, pharmaceutical companies, insurance companies and third-party organizations are working closely together to create a comprehensive medical health ecosystem that will enhance access to humane care and innovative treatment for cancer patients through science and technology.
Innovative "Hui Chang Care" online patient integrated service platform, so that patients can get the authority of professional patient education live, convenient and fast online drug purchase map, easy to find drugs (cloud pharmacy) and other convenient multi-dimensional patient services.
on this basis, all walks of life are still vigorously promoting China's diagnosis and treatment technology, the concept of continuous progress, to maximize the satisfaction of China's advanced breast cancer patients unsophatic medical needs, to help patients with scientific anti-cancer, with the power of love to break through the impossible life! medsci Source: medsci Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not reproduced by any media, website or individual without authorization, and must be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here